Dr. John P. Donoghue Wins Germany's Top Neuroscience Honor for Development of Cyberkinetics' BrainGate System

Cyberkinetics Neurotechnology Systems, Inc. (OTCBB:CYKN; "Cyberkinetics”) announced that John P. Donoghue, Ph.D., Cyberkinetics’ Chief Scientific Officer and director of the Brain Science Program at Brown University, will be awarded the K. J. Zülch Prize, Germany’s highest honor for neurological research. Dr. Donoghue is being recognized for his groundbreaking research on the BrainGate Neural Interface System (BrainGate), a technology designed to enable severely paralyzed people to use thought alone to operate a variety of assistive devices, such as a computer cursor and a wheelchair. The Zülch Prize, which is bestowed by the Gertrud Reemtsma Foundation through the Max Planck Society, is awarded annually to two scientists for outstanding achievements. This year, Dr. Donoghue will share the award, along with a cash prize of 50,000 Euros (approximately $68,300), with Graeme Clark, developer of the cochlear implant (bionic ear). The prize will be awarded at a ceremony on August 31, 2007, in Cologne, Germany. Previous recipients of the Zülch Prize include: Nobel Laureate Stanley B. Prusiner, M.D., who discovered the infectious proteins called prions; Nikos K. Logothetis, Ph.D., who pioneered functional magnetic resonance imaging in vision research; Samuel F. Berkovic, M.D., who determined the genetic basis for epilepsy; and Fred H. Gage, Ph.D., who spearheaded research that showed human beings are capable of growing new nerve cells throughout life. "We congratulate John for this well deserved international recognition of his pioneering research, which has led to the development of Cyberkinetics’ BrainGate program,” stated Timothy R. Surgenor, Cyberkinetics’ President and Chief Executive Officer. "John’s efforts to bring cutting-edge, basic science to bear on the lives of the severely disabled are an inspiration to all of us at Cyberkinetics.” Dr. Donoghue is the Henry Merritt Wriston Professor at Brown University. A leader in neuroprosthesis research and development, his work centers on understanding how networks of neurons within the brain process complex information that results in skilled voluntary movement. About the BrainGate Neural Interface System The BrainGate Neural Interface System is a proprietary, investigational brain-computer interface (BCI) that consists of an internal sensor to detect brain cell activity and external processors that convert these brain signals into a computer-mediated output under the person's own control. The sensor is a tiny silicon chip about the size of a baby aspirin with one hundred electrodes, each thinner than a human hair, that can detect the electrical activity of neurons. The sensor is implanted on the surface of the area of the brain responsible for movement, the motor cortex. A small wire connects the sensor to a pedestal that is placed on the skull, extending through the scalp. An external cable connects the pedestal to a cart containing computers, signal processors and monitors that enable the study operators to determine how well study participants can control devices driven by their neural output - that is, by thought alone. The ultimate goal of the BrainGate System development program is to create a safe, effective and unobtrusive universal operating system that will enable those with motor impairments resulting from a variety of causes to quickly and reliably control a wide range of devices, including computers, assistive technologies and medical devices, simply by using their thoughts. The fundamental groundwork for this human clinical work was conducted in the Donoghue lab at Brown University and made possible by preclinical funding from the National Institute of Neurological Disorders and Stroke. About the Max Planck Society The Max Planck Society for the Advancement of Science is an independent, non-profit research organization. Founded on February 26, 1948, the primary goal of the Max Planck Society is to perform basic research in the interest of the general public in the natural sciences, life sciences, social sciences, and the humanities. Since its founding, the Max Planck Society boasts 16 Nobel Prize recipients. Additional information is available at http://www.mpg.de/english/portal/index.html. About Cyberkinetics Neurotechnology Systems, Inc. Cyberkinetics Neurotechnology Systems, Inc., a leader in the neurotechnology industry, is developing neural stimulation, sensing and processing technology to improve the lives of those with severe paralysis resulting from spinal cord injuries, neurological disorders and other conditions of the nervous system. Cyberkinetics’ product development pipeline includes: Andara™ OFS™ Therapy for acute spinal cord injury, an investigative device designed to stimulate nerve repair and restore sensation and motor function; the BrainGate System, an investigative device designed to provide communication and control of a computer, assistive devices, and, ultimately, limb movement; and a pilot program in the detection and prediction of seizures due to epilepsy. Additional information is available at Cyberkinetics’ website at http://www.cyberkineticsinc.com. Forward-Looking Statements This announcement contains forward-looking statements, including statements about Cyberkinetics' product development plans and progress, potential development of proprietary inventions and benefits that may be realized by certain research programs. Such statements may be considered "forward-looking” within the meaning of the United States Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of words like "may,” "will,” "could,” "should,” "project,” "believe,” "anticipate,” "expect,” "plan,” "estimate,” "forecast,” "potential,” "intend,” "continue” and variations of these words or comparable words. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Forward-looking statements include, but are not limited to, statements concerning our future expectations, plans, prospects and future operating results as well as projections of cash and marketable securities and sufficiency of funding for capital expenditures. Actual results may differ materially from those indicated by these forward-looking statements as a result of various factors including risks related to: our ability to secure regulatory approval for our products; our access to additional capital; our ability to obtain additional funding to support our business activities; our dependence on third parties for development, manufacture, marketing, sales and distribution of our products; our development of products; our ability to obtain and maintain patent protection for our discoveries and products; and our limited operating history; as well as those risks more fully discussed in the "Risk Factors" section of the Company’s Registration Statement on Form SB-2 (file no. 333-144333) and our other public documents filed with the SEC. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date.